This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Company News For Dec 11, 2017
by Zacks Equity Research
Companies in the news are: GILD,AOBC,UNFI,UAL
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
by Arpita Dutt
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.
Gilead Sciences to Acquire Cell Design Labs for $567 Million
by Zacks Equity Research
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
5 Biotech and Pharma Stocks with FDA Catalysts this December
by Arpita Dutt
As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
How Will U.S. Tax Reform Impact Pharma/Biotech Industry?
by Zacks Equity Research
After certain modifications to the original plan over the past year, the tax reform bill is expected to be voted on by the Congress this week. Let's see how this vote will impact the pharma/biotech industry.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Gilead (GILD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAR-T Therapy Space 2017 Progress Report
by Zacks Equity Research
Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.
Biotech Poised for Growth: 3 Healthy Fund Choices
by Zacks Equity Research
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted
by Arpita Dutt
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.
5 Biotech and Pharma Stocks with Key FDA Catalysts this November
by Arpita Dutt
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
Company News For Oct 30, 2017
by Zacks Equity Research
Companies in the news are: GILD, AXTA, B, AON
Top Research Reports for JPMorgan Chase, Gilead & ConocoPhillips
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Gilead (GILD) and ConocoPhillips (COP).
Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat
by Zacks Equity Research
Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.
Gilead (GILD) Q3 Earnings and Revenues Sink
by Benjamin Rains
Gilead Sciences, Inc. (GILD) just released its third-quarter 2017 financial results, posting earnings of $2.06 per share and revenues of $6.51 billion.